Pitolisant in Refractory Restless Legs Syndrome

Status Recruiting

Clinical Trial Summary

This is an open-label trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy, defined by an IRLS score greater than 15. Investigators hypothesize that the study drug, Pitolisant (Wakix), may improve RLS symptoms.

Clinical Trial Description

This is an open-label trial in RLS patients who have been inadequately treated with standard therapies, defined by an IRLS > 15. This trial consists of four study center visits (weeks 0, 4, 8, and 16) and four telephone visits (weeks 1, 3, 11, and a post safety phone call at week 17). Subjects will titrate pitolisant for three weeks, starting with a dose of 8.9 mg at week 1, then increase to 17.8 mg at week 2, and a final increase to maximum dosage of 35.6 mg at week 3. If subjects are unable to tolerate the highest dose, they may reduce their dose to 17.8 mg. Titration of the drug will be monitored via telephone visits. During weeks 0-8, subjects will continue to take their current RLS medications. From week 8-16, subjects may either reduce or stop their other RLS medications as mutually agreed upon with investigator. Several questionnaire assessments will be conducted throughout the study to monitor the subjects. Subjects will complete the International RLS Rating Scale (IRLS), Restless Legs Syndrome - 6 Scale (RLS-6), RLS Quality of Life Questionnaire (RLSQoL), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HDS), Montreal Cognitive Assessment (MoCA), Epworth Sleepiness Scale (ESS), Clinical Global Impressions (CGI), and Clinical Global Impressions-Change (CGI-C). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05581576
Study type	Interventional
Source	The Methodist Hospital Research Institute
Contact	William Ondo, MD
Phone	7133638184
Email	wondo@houstonmethodist.org
Status	Recruiting
Phase	Phase 4
Start date	September 20, 2022
Completion date	May 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04786314` - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome	N/A
Completed	`NCT01455012` - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome	Phase 4
Terminated	`NCT01192503` - Safety and Efficacy of Rasagiline in Restless Legs Syndrome	Phase 2/Phase 3
Completed	`NCT00721279` - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome	N/A
Completed	`NCT00530530` - ASP8825 - Study in Patients With Restless Legs Syndrome	Phase 2
Completed	`NCT00375284` - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS	Phase 4
Completed	`NCT00942253` - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)	Phase 2
Completed	`NCT00479531` - Sequential Compression Devices for Treatment of Restless Legs Syndrome	Phase 3
Active, not recruiting	`NCT03218969` - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist	Phase 1/Phase 2
Recruiting	`NCT04144790` - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed	`NCT05787080` - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)	N/A
Not yet recruiting	`NCT05529095` - Sublingual Apomorphine in Refractory Restless Legs Syndrome	Phase 4
Recruiting	`NCT05044520` - Clinical Features Associated With Restless Legs Syndrome.
Withdrawn	`NCT03849001` - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS	N/A
Completed	`NCT03076541` - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.	N/A
Recruiting	`NCT04145674` - A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo	Phase 2
Completed	`NCT02532608` - Infra-slow Oscillations During Sleep	N/A
Completed	`NCT01528462` - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed	`NCT00748098` - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance	Phase 3
Completed	`NCT00373542` - 12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome	Phase 4